# Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors

> **NCT07360314** · PHASE1 · RECRUITING · sponsor: **EMD Serono Research & Development Institute, Inc.** · enrollment: 138 (estimated)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **DRUG:** M7437
- **DRUG:** M7437

## Key facts

- **NCT ID:** NCT07360314
- **Lead sponsor:** EMD Serono Research & Development Institute, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-02-13
- **Primary completion:** 2028-09-20
- **Final completion:** 2029-03-28
- **Target enrollment:** 138 (ESTIMATED)
- **Last updated:** 2026-05-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07360314

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07360314, "Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT07360314. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*